


a) Summary of pre-pandemic controls and vaccinated cohorts

Variables	Pre-pandemic Controls	Comirnaty / BNT162b2 (Pfizer-BioNtech) vaccines	COVID-19 Recovered (Convalescent, vaccinated) (n=10)	ChAdOx1 nCoV-19 (AstraZeneca) vaccines
	Pre-pandemic (n=20)	Vaccinated only (n=20)	(n=10)	Vaccinated only (n=17)
Age, mean (range), years	30.5 (21 – 60)	34.6 (26 – 58)	49.5 (24 – 65)	46.5 (23 – 69)
Gender				
Female (%)	16 (80.0%)	13 (65.0%)	6 (60.0%)	10 (58.8%)
Male (%)	4 (20.0%)	7 (35.0%)	4 (40.0%)	7 (41.2%)
Time from symptom onset till sample collection, mean (range), days			478.1 (412 – 534)	
Vaccination				
Time after 1 st shot till sample collection, mean (range), days		9.1 (6 – 12)	12.5 (7 – 18)	13.4 (7 – 22)
Time between 1 st and 2 nd shot, mean (range), days		24.0 (21 – 33)	28.0 (21 – 48)	83 (70 – 92)
Time after 2 nd shot till sample collection, mean (range), days		14.1 (12 – 22)	20.1 (10 – 34)	13.4 (7 – 22)
Time between 2 nd shot and 5 months sample collection, mean (range), days		218.8 (188 – 226)		149.6 (101 – 184)
Time after 3 rd shot till sample collection, mean (range), days		12.4 (10 – 15)		20.1 (10 – 31)


b) Summary of breakthrough cohorts


	Delta breakthroughs (n=8)	Omicron BA.2 breakthroughs (n=10)
Variables		
Age, mean (range), years	34.6 (19 – 58)	54.3 (40 – 66)
Gender		
Female (%)	5 (62.5%)	5 (50.0%)
Male (%)	3 (37.5%)	5 (50.0%)
Vaccination doses prior to breakthrough infection (%)	2 (100.0%)	3 (100.0%)
Time from last vaccination till breakthrough infection, mean (range), months	3.3 (0.3 – 5.3)	3.2 (1.6 – 5.3)


c) Sampling timepoints for breakthrough infections




d) Schematic of SARS-CoV-2 spike protein











Plasma antibody signatures following BNT162b2 vaccination




Plasma antibody comparisons after two antigen exposures




Plasma antibody comparisons after three antigen exposures




Comparisons of plasma anti-Spike 2 responses after mRNA boosters in vaccinated only cohort




ChAdOx1 nCoV-19 vaccinated cohort timepoints



Saliva and plasma antibody signatures following ChAdOx1 nCoV-19 vaccination




Breakthrough infections, viral load kinetics




Saliva SARS-CoV-2 VoC antibody signatures following breakthrough infections

% ACE2 Inhibition (≤ 5 days vs 2 weeks post-onset)




FcγR3a Responses (≤ 5 days vs 2 weeks post-onset)




Plasma SARS-CoV-2 VoC antibody signatures following breakthrough infections



% ACE2 Inhibition (≤ 5 days vs 2 weeks)




FcγR3a Responses (≤ 5 days vs 2 weeks)



Breakthrough infections, comparison of antibody responses vs viral load



Saliva antibody responses over time, breakthrough infections



Plasma antibody responses over time, breakthrough infections

